 Hoth Therapeutics, Inc. NASDAQ: HOTH, a biopharmaceutical company, today announced it has executed a licensing agreement with Isoprene Pharmaceuticals, Inc. to acquire the rights to VNLG-152, a novel retinamides Retinoic acid metabolism blocking agents, or RAMBAs for the treatment of dermatological diseases. Isoprene is a cancer therapeutic company that is a University of Maryland, Baltimore New Venture Initiative start-up. 